MDWD News and Press, MediWound Ltd. From 08/05/19

Gainers: Allakos (NASDAQ: ALLK ) +129% . MediWound (NASDAQ: MDWD ) +15% . Four Seasons Education (Cayman) (NYSE: FEDU ) +12%  KemPharm (NASDAQ: KMPH ) +12% .  Sandstorm Gold (NYSEMKT: SAND ) +11% . Endeavour Silver (NYSE: EXK ) +10% . MoneyGram International (NASDAQ: MGI )...

Company’s primary focus turns to EscharEx following its successful collaboration for NexoBrid Company to initiate an adaptive comprehensive adequately controlled study in 4Q 2019 Company to host Analyst Day today, July 22, in New York, NY YAVNE, Israel, July 22, 2019 (GLO...

The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) was in the red again last week, falling from  3,324.66 points on Monday’s open to 3,314.13 points as of 1:54 p.m. EDT on Friday (July 19). On Sunday (July 14), Gilead Sciences (NASDAQ: GILD ) announced its plans to play US$5.1 ...

YAVNE, Israel, July 16, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, will host an analyst day on its innovative product for chronic wounds on Mon...

YAVNE, Israel, June 11, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced the appointment of Mr. Boaz Gur-Lavie as Chief Financial Off...

For a year, Vericel ( VCEL ) teased investors with hints that it would be adding an acquisition to its product line. After doing a large, surprise secondary offering of $75 million in June 2018, Vericel indicated it was actively on the hunt for " commercial products or businesses which would ...

YAVNE, Israel, June 04, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced receipt of authorization from the Ministry of Health in Peru...

Total non-dilutive funds for NexoBrid now valued at up to $196 Million MediWound to initiate NexoBrid expanded access treatment protocol (NEXT) in the third quarter of 2019, allowing for ongoing use of NexoBrid to treat burn patients in U.S. YAVNE, Israel, May 29, 2019 (GLOBE NEWSWIRE) ...

MediWound Ltd. (MDWD) Q1 2019 Results Earnings Conference Call May 21, 2019, 8:30 AM ET Company Participants Jeremy Feffer - Managing Director Steve Wills - Chairman Sharon Malka - Chief Executive Officer Conference Call Participants Raj Denhoy - Jefferies Josh Jennings -...

YAVNE, Israel, May 14, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the f...